Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
复制标题

DOI:
10.1002/mds.25594
复制
发表时间:
2013-09
期刊:
影响因子:
8.6
通讯作者:
Zhang, Danhui
Zhang, Danhui
中科院分区:
医学1区
文献类型:
--
作者:
Quik, Maryka;Mallela, Archana;Ly, Jason;Zhang, Danhui

文献摘要

参考文献

被引文献

相似文献

Although 3,4-dihydroxyphenylalanine (L-dopa) is the gold-standard treatment for Parkinson’s disease, it can lead to disabling dyskinesias. Previous work showed that nicotine reduces L-dopa-induced dyskinesias (LIDs) in several parkinsonian animal models. The goal of this study was to determine if the time of nicotine administration affected its ability to reduce LIDs in L-dopa-primed and L-dopa naïve monkeys, and also to test if tolerance developed to nicotine’s beneficial effects. Monkeys were injected with MPTP (1.9–2.0 mg/kg sc) over 3–5 months until parkinsonian. Nicotine (300 μg/ml) was administered in drinking water (4–6 months) to L-dopa-primed or L-dopa-naïve monkeys, with L-dopa/carbidopa (10/2.5 mg/kg) gavaged twice daily. One set of MPTP-lesioned monkeys (n=23) was first gavaged with L-dopa and subsequently given nicotine 4 wk later when dyskinesias have plateaud or 8 wk later when dyskinesias are established. A 60–70% decrease in LIDs was observed after several weeks of nicotine treatment in both groups. A second set of monkeys (n=26) was given nicotine 8 or 2 weeks before L-dopa. In the 8 week nicotine pretreatment group, there was an immediate reduction in LIDs, which plateaud at 60–70%. In the 2 week nicotine pretreatment group, there were initial small decreases in LIDs, which plateaud at 60–70% several weeks later. Thus, nicotine pre- and post-treatment was similarly efficacious in reducing LIDs. The beneficial effect of nicotine persisted throughout the study (17–23 weeks). Nicotine did not worsen parkinsonism. These data suggest that nicotine treatment has potential as a successful antidyskinetic therapy for Parkinson’s disease patients.
DOI: 10.1046/j.1471-4159.2002.00868.x
发表时间: 2002-04-01
影响因子: 4.7
作者:
Kulak, JM;Sum, J;Quik, M
通讯作者: Quik, M
DOI: 10.1016/s0079-6123(10)83011-0
发表时间: 2010
影响因子: --
作者:
Cenci, M. Angela;Konradi, Christine
通讯作者: Konradi, Christine
DOI: 10.1016/j.bcp.2009.05.024
发表时间: 2009-10-01
影响因子: 5.8
作者:
Gotti, Cecilia;Clementi, Francesco;Zoli, Michele
通讯作者: Zoli, Michele
DOI: 10.1124/jpet.111.182949
发表时间: 2011-09-01
影响因子: 3.5
作者:
Huang, Luping Z.;Grady, Sharon R.;Quik, Maryka
通讯作者: Quik, Maryka
DOI: 10.1016/j.neuropharm.2010.12.032
发表时间: 2011-05
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Huang, Luping Z.;Campos, Carla;Ly, Jason;Carroll, F. Ivy;Quik, Maryka
通讯作者: Quik, Maryka